

**Gary A. Dildy III, MD**

Clinical Professor, Department of Obstetrics and Gynecology, Louisiana State University Health Sciences Center New Orleans

Director of Site Analysis  
HCA Perinatal Quality Assurance  
Nashville, Tenn

Staff Perinatologist  
Maternal-Fetal Medicine  
St. Mark's Hospital  
Salt Lake City, Utah

**OBSTETRIC EMERGENCIES**

**Management of prolonged decelerations**

Some are benign, some are pathologic but reversible, and others are the most feared complications in obstetrics

**A** prolonged deceleration may signal danger—or reflect a perfectly normal fetal response to maternal pelvic examination. Because of the wide range of possibilities, this fetal heart rate pattern justifies close attention. For example, repetitive prolonged decelerations may indicate cord compression from oligohydramnios. Even more troubling, a prolonged deceleration may occur for the first time during the evolution of a profound catastrophe, such as amniotic fluid embolism or uterine rupture during vaginal birth after cesarean delivery (VBAC). In some circumstances, a prolonged deceleration may be the terminus of a progression of nonreassuring fetal heart rate (FHR) changes, and becomes the immediate precursor to fetal death (TABLE 1).<sup>1</sup>

When FHR patterns exhibit these aberrations, we rightly worry about fetal well-being and the possible need for operative intervention. Unfortunately, the degree of fetal compromise is difficult to predict and depends on preexisting fetal condition, physiologic reserve, degree and duration of the insult, and other variables.

**Ultimately, a judgment call**

The 22nd edition of *Williams Obstetrics*<sup>2</sup> summarizes the clinical challenges involved in the management of prolonged decelerations during labor: “Management of isolated prolonged decelerations is based on bedside clinical judgment, which inevitably will sometimes be imperfect given the unpredictability of these decelerations.”

**“Fetal bradycardia” and “prolonged deceleration” are distinct entities**

In general parlance, we often use the terms “fetal bradycardia” and “prolonged deceleration” loosely. In practice, we must differentiate these entities because underlying pathophysiologic mechanisms and clinical management may differ substantially.

The problem: Since the introduction of electronic fetal monitoring (EFM) in the 1960s, numerous descriptions of FHR patterns have been published, each slightly different from the others. The result: confusing nomenclature, miscommunication among clinicians, and stymied research efforts.

To standardize definitions of intrapartum FHR patterns so that the effectiveness of EFM could be better assessed in observational studies and clinical trials, the National Institute of Child Health and Human Development organized a workshop.<sup>3</sup> Its recommendations were subsequently adopted by the American College of Obstetricians and Gynecologists (ACOG).<sup>4</sup> Among the definitions:

- **Bradycardia:** a baseline FHR of less than 110 beats per minute.

**IN THIS ARTICLE**

**3 FHR patterns:**

**What would you do?**

Complete heart block

Prolonged deceleration during pelvic exam

Uterine rupture  
Page 38

**6 pearls for managing prolonged decelerations**

Page 45

TABLE 1

## Some causes of prolonged decelerations and bradycardias

PROLONGED DECELERATION	BRADYCARDIA
<p><b>Cord compression</b> Oligohydramnios Cord prolapse</p> <p><b>Uteroplacental insufficiency</b> Anesthesia (paracervical, spinal, epidural) Maternal valsalva Maternal supine hypotension Hypertonic or prolonged contractions Abruptio placentae Uterine rupture Cocaine ingestion</p> <p><b>Maternal hypoxia</b> Maternal seizures, eclampsia Respiratory depression from medications Cardiopulmonary arrest Amniotic fluid embolism</p> <p><b>Fetal hemorrhage</b> Vasa previa Traumatic amniocentesis</p> <p><b>Fetal vagal reaction</b> Rapid descent, impending birth Cervical examination Fetal scalp electrode placement Fetal blood sampling</p> <p><b>Fetal central nervous system anomalies</b> <b>Idiopathic</b> (cord compression?)</p>	<p><b>Congenital conduction abnormalities</b> Complete heart block Long QT syndrome Congenital heart defects Tachyarrhythmia (Fetal tachyarrhythmia may produce an EFM tracing that appears to be a bradycardia and can only be distinguished by ultrasound)</p> <p><b>Medications</b> Beta blockers</p> <p><b>Hypothermia</b></p> <p><b>Infection</b> Chorioamnionitis Endotoxemia</p>

- **Prolonged deceleration:** a visually apparent decrease of 15 or more beats per minute below the baseline. This decrease lasts at least 2 minutes but less than 10 minutes from onset to the return to baseline ( $\geq 10$  minutes is considered a baseline change).

**Differentiation between the 2 entities is critical** because, in many cases, bradycardias are chronic patterns that may not be associated with immediate fetal compromise and do not require immediate intervention. For example, a fetal bradycardia due to congenital heart block would not benefit from immediate delivery, especially prior to term.

“Moderate fetal bradycardia,” defined as a baseline of 100 to 119 bpm, was reported in 1.8% of 1,386 continuously monitored patients and is attributed to relative cephalopelvic disproportion,

resolving after rotation of the fetal vertex and associated with normal neonatal outcome.<sup>5,6</sup>

### ■ Similar decelerations can reflect different events

The exact depth and duration of a prolonged deceleration leading to fetal compromise and requiring prompt delivery is difficult to define, although some observations warrant consideration. Experiments with fetal lambs show that the deceleration in response to umbilical vein occlusion is associated with a fall in fetal blood pressure, whereas deceleration in response to umbilical artery occlusion is associated with a rise in fetal blood pressure. This reflex can be abolished by vagotomy, but will eventually recur due to anoxia.<sup>7</sup>

### **FAST TRACK**

**Fetal bradycardias and prolonged decelerations are 2 distinct entities; the first usually does not warrant immediate intervention**

CONTINUED

75 years of age. In women greater than 75, the increased risk of non-fatal stroke and invasive breast cancer observed in the estrogen-plus-progestin combination group compared to the placebo group was 75 vs. 24 per 10,000 women-years and 52 vs. 12 per 10,000 women-years, respectively.

In the estrogen-plus-progestin WHIMS substudy, a population of 4,532 postmenopausal women, aged 65 to 79 years, was randomized to CE/MPA (0.625 mg/2.5 mg daily) or placebo. In the estrogen-plus-progestin group, after an average follow-up of four years, the relative risk (CE/MPA vs. placebo) of probable dementia was 2.05 (95% CI 1.21-3.48). The absolute risk of developing probable dementia with CE/MPA was 45 vs. 22 cases per 10,000 women-years with placebo.

Seventy-nine percent of the cases of probable dementia occurred in women that were older than 70 for the CE group, and 82 percent of the cases of probable dementia occurred in women who were older than 70 in the CE/MPA group. The most common classification of probable dementia in both the treatment groups was Alzheimer's disease.

When data from the two populations were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable dementia was 1.76 (95% CI 1.19-2.60). Since both substudies were conducted in women aged 65 to 79 years, it is unknown whether these findings apply to younger postmenopausal women. (See **BOXED WARNINGS** and **WARNINGS, Dementia**.)

With respect to efficacy in the approved indications, there have not been sufficient numbers of geriatric patients involved in studies utilizing Premarin to determine whether those over 65 years of age differ from younger subjects in their response to Premarin.

**ADVERSE REACTIONS**  
See **BOXED WARNINGS, WARNINGS, and PRECAUTIONS.**

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.

During the first year of a 2-year clinical trial with 2,333 postmenopausal women between 40 and 65 years of age (88% Caucasian), 1,012 women were treated with conjugated estrogens and 332 were treated with placebo. Table 6 summarizes adverse events that occurred at a rate of  $\geq 5\%$ .

**TABLE 6. NUMBER (%) OF PATIENTS REPORTING  $\geq 5\%$  TREATMENT EMERGENT ADVERSE EVENTS**

Body System Adverse event	— Conjugated Estrogens Treatment Group —			
	0.625 mg (n = 348)	0.45 mg (n = 338)	0.3mg (n = 326)	Placebo (n = 332)
Any adverse event	323 (93%)	305 (90%)	292 (90%)	281 (85%)
Body as a Whole				
Abdominal pain	56 (16%)	50 (15%)	54 (17%)	37 (11%)
Accidental injury	21 (6%)	41 (12%)	20 (6%)	29 (9%)
Asthenia	25 (7%)	23 (7%)	25 (8%)	16 (5%)
Back pain	49 (14%)	43 (13%)	43 (13%)	39 (12%)
Flu syndrome	37 (11%)	38 (11%)	33 (10%)	35 (11%)
Headache	90 (26%)	109 (32%)	96 (29%)	93 (28%)
Infection	61 (18%)	75 (22%)	74 (23%)	74 (22%)
Pain	58 (17%)	61 (18%)	66 (20%)	61 (18%)
Digestive System				
Diarrhea	21 (6%)	25 (7%)	19 (6%)	21 (6%)
Dyspepsia	33 (9%)	32 (9%)	36 (11%)	46 (14%)
Flatulence	24 (7%)	23 (7%)	18 (6%)	9 (3%)
Nausea	32 (9%)	21 (6%)	21 (6%)	30 (9%)
Musculoskeletal System				
Arthralgia	47 (14%)	42 (12%)	22 (7%)	39 (12%)
Leg cramps	19 (5%)	23 (7%)	11 (3%)	7 (2%)
Myalgia	18 (5%)	18 (5%)	29 (9%)	25 (8%)
Nervous System				
Depression	25 (7%)	27 (8%)	17 (5%)	22 (7%)
Dizziness	19 (5%)	20 (6%)	12 (4%)	17 (5%)
Insomnia	21 (6%)	25 (7%)	24 (7%)	33 (10%)
Nervousness	12 (3%)	17 (5%)	6 (2%)	7 (2%)
Respiratory System				
Cough increased	13 (4%)	22 (7%)	14 (4%)	14 (4%)
Pharyngitis	35 (10%)	35 (10%)	40 (12%)	38 (11%)
Rhinitis	21 (6%)	30 (9%)	31 (10%)	42 (13%)
Sinusitis	22 (6%)	36 (11%)	24 (7%)	24 (7%)
Upper respiratory infection	42 (12%)	34 (10%)	28 (9%)	35 (11%)
Skin and Appendages				
Pruritus	14 (4%)	17 (5%)	16 (5%)	7 (2%)
Urogenital System				
Breast pain	38 (11%)	41 (12%)	24 (7%)	29 (9%)
Leukorrhea	18 (5%)	22 (7%)	13 (4%)	9 (3%)
Vaginal hemorrhage	47 (14%)	14 (4%)	7 (2%)	0
Vaginal moniliasis	20 (6%)	18 (5%)	17 (5%)	6 (2%)
Vaginitis	24 (7%)	20 (6%)	16 (5%)	4 (1%)

The following additional adverse reactions have been reported with estrogen and/or progestin therapy:

1. **Genitourinary system**

Changes in vaginal bleeding pattern and abnormal withdrawal bleeding or flow; breakthrough bleeding, spotting, dysmenorrhea; increase in size of uterine leiomyomata; vaginitis, including vaginal candidiasis; change in amount of cervical secretion; change in cervical ectropion; ovarian cancer; endometrial hyperplasia; endometrial cancer.

2. **Breasts**

Tenderness, enlargement, pain, discharge, galactorrhea, fibrocystic breast changes; breast cancer.

3. **Cardiovascular**

Deep and superficial venous thrombosis, pulmonary embolism, thrombophlebitis, myocardial infarction, stroke, increase in blood pressure

4. **Gastrointestinal**

Nausea, vomiting; abdominal cramps, bloating; cholestatic jaundice; increased incidence of gallbladder disease; pancreatitis; enlargement of hepatic hemangiomas.

5. **Skin**

Chloasma or melasma that may persist when drug is discontinued; erythema multiforme; erythema nodosum; hemorrhagic eruption; loss of scalp hair; hirsutism; pruritus, rash.

6. **Eyes**

Retinal vascular thrombosis, intolerance to contact lenses

7. **Central Nervous System**

Headache, migraine, dizziness, mental depression, chorea, nervousness, mood disturbances, irritability, exacerbation of epilepsy, dementia.

8. **Miscellaneous**

Increase or decrease in weight; reduced carbohydrate tolerance; aggravation of porphyria; edema; arthralgias; leg cramps; changes in libido; urticaria, angioedema, anaphylactoid/anaphylactic reactions; hypocalcemia; exacerbation of asthma; increased triglycerides.

**OVERDOSAGE**

Serious ill effects have not been reported following acute ingestion of large doses of estrogen-containing drug products by young children. Overdosage of estrogen may cause nausea and vomiting, and withdrawal bleeding may occur in females.

This brief summary is based on PREMARIN® (conjugated estrogens tablets, USP)

Prescribing Information W104050017 ET01, revised April 2006.

Wyeth®

© 2006, Wyeth Pharmaceuticals Inc., Philadelphia, PA 19101

119964-01

**Vital clue: What happened before the prolonged deceleration?**

In clinical practice, it is important to appreciate characteristics of the FHR pattern preceding the prolonged deceleration.<sup>8</sup> Williams and Galerneau<sup>9</sup> correlated baseline FHR variability and duration of prolonged decelerations with neonatal acid-base status in 186 term gestations with an identified prolonged deceleration within 30 minutes of delivery. Patients were divided into 4 groups, based on FHR variability and recovery of the FHR baseline (TABLE 2).

The findings:

- **Lowest cord pH** was associated with decreased variability without recovery of the FHR
- **Neonatal acidemia** was most strongly correlated with decreased variability before the prolonged deceleration

**Acid-base changes likely begin within minutes of cord compression**

Ziliani and colleagues<sup>10</sup> evaluated 29 fetuses with normal FHR patterns during labor with FHR deceleration during the expulsion phase of delivery. When the FHR deceleration was prolonged (>120 seconds), umbilical artery pH significantly decreased (7.19 vs 7.27), umbilical vein pH remained unchanged (7.32), and the umbilical venous-arterial pH difference was significantly increased (0.13 vs 0.05). Thus, acid-base changes likely begin within minutes of cord compression.


**The correlation between acidemia and loss of variability**

In their review of 43 vacuum extractions, Gull and colleagues<sup>22</sup> found that 27 infants were delivered for “end-stage bradycardia” (abrupt persistent decrease in FHR to less than 100 bpm for more than 2 minutes, or repeated deceleration more than 60 bpm below baseline with poor recovery), and 16 were delivered electively (controls). Umbilical-cord base deficit was greater in the newborns with bradycardia than in controls, and the length of time FHR variability was lost correlated with the degree of base deficit. Acidemic fetuses

CONTINUED

# 3 fetal heart rate patterns: What would you do?

## Complete heart block




### Dilemma


Fetal bradycardia due to congenital complete heart block secondary to anti-SS-A/Ro and anti-SS-B/La antibodies. The fetal ventricular rate is fixed at 60 bpm

### Management

At 30 weeks' gestation, with no sonographic evidence of heart failure and a biophysical profile score of 8/8, expectant management is indicated



## Prolonged deceleration during pelvic exam




### Dilemma


Prolonged deceleration during pelvic examination in an uncomplicated term pregnancy. Note that fetal heart rate (FHR) variability was maintained during recovery of the FHR baseline

### Outcome

Uneventful spontaneous vaginal delivery



## Uterine rupture




### Dilemma

Prolonged deceleration due to uterine rupture during trial of labor after cesarean. Repetitive variable decelerations preceded the prolonged deceleration. FHR variability was lost after several minutes

### Outcome

Emergency cesarean



**TABLE 2**

**Neonatal outcomes associated with variability and recovery of FHR patterns after prolonged deceleration**

UMBILICAL ARTERY	GROUP 1 V+ R+ (N = 128)	GROUP 2 V+ R- (N = 40)	GROUP 3 V- R+ (N = 9)	GROUP 4 V- R- (N = 9)	P VALUE
pH (mean ± SD)	7.17 ± 0.09	7.13 ± 0.15	7.11 ± 0.11	6.83 ± 0.16	<.001
Base deficit (mean ± SD)	-6.5 ± 3.9	-7.2 ± 5.1	-10 ± 4	-20 ± 6	<.001
pH <7.0 (%)	2	18	44	78	<.001
pH <7.1 (%)	22	33	56	89	<.001
Base deficit <16 (%)	1	8	11	78	<.001
Base deficit <12 (%)	5	13	22	89	<.001

V = variability  
R = recovery  
SOURCE: Williams and Galerneau<sup>9</sup>

lost FHR variability during the bradycardia for more than 4 minutes, or started to lose FHR variability less than 3 minutes from the beginning of the bradycardia.

**What is optimal interval between deceleration and delivery?**

In a series of 106 cases of uterine rupture during VBAC, Leung et al<sup>11</sup> found significant neonatal morbidity when 18 minutes or more lapsed between the onset of the prolonged deceleration and delivery.

**■ First, remain calm when decelerations occur**

Freeman and colleagues<sup>12</sup> advocate staying calm and avoiding overreaction, because many cases will resolve spontaneously. Nonetheless, prolonged decelerations should prompt the physician to:

- consider the underlying pathophysiology and implement corrective interventions (TABLE 3)
- further assess fetal condition
- prepare for the possibility of immediate delivery (TABLE 4)

**Consider amnioinfusion when cord compression is suspected**

Many cases of prolonged decelerations are secondary to cord compression resulting

from oligohydramnios. Miyazaki<sup>13</sup> showed that saline amnioinfusion helped correct the FHR problem in most cases of repetitive variable decelerations (19 of 28) and prolonged decelerations (12 of 14 cases).

Several randomized clinical trials analyzed in a recent Cochrane Review<sup>14</sup> suggest that amnioinfusion for cord compression reduces the occurrence of variable FHR decelerations and the need for cesarean section; this applies to settings in which nonreassuring FHR patterns were not further assessed by fetal blood sampling, which is reflective of practice in most US labor units.

The recent ACOG practice bulletin on intrapartum monitoring<sup>4</sup> advocates amnioinfusion for recurrent variable FHR decelerations, but does not address prolonged decelerations specifically.

Although most data on amnioinfusion address treatment of recurrent variable FHR decelerations, it also seems reasonable to consider this option for prolonged decelerations when oligohydramnios is suspected.<sup>12</sup>

**Other possible causes of prolonged decelerations**

**Vasa previa.** A sudden prolonged deceleration following rupture of membranes with concomitant vaginal bleeding should prompt the physician to consider the pos-

CONTINUED

**FAST TRACK**

**Amnioinfusion for cord compression reduces variable FHR decelerations and the need for cesarean section**

TABLE 3

## 6 pearls for managing prolonged decelerations

	GOAL	PEARL
1	Reduce aorto-caval and/or cord compression	Change patient positioning
2	Restore intravascular volume	Administer intravenous fluid bolus
3	Reduce uterine activity	Discontinue oxytocin drip and give tocolytic therapy (terbutaline)
4	Enhance oxygen delivery to fetus	Give supplemental oxygen
5	Resolve hypotension	Administer vasopressor therapy (ephedrine)
6	Resolve oligohydramnios and cord compression	Perform transcervical amnioinfusion

sibility of a disrupted velamentous cord insertion (vasa previa), which can lead to rapid fetal exsanguination.<sup>15</sup>

**Acute profound maternal hypoxemia** may lead to a first prolonged FHR deceleration, often preceded by increased uterine tone, as described in both eclampsia<sup>16</sup> and amniotic fluid embolism.<sup>17</sup> With eclampsia, the prolonged deceleration is reversible; treatment and expectant management will allow for fetal recovery after the seizure abates.

When acute amniotic fluid embolism leads to profound cardiovascular collapse, prompt perimortem cesarean delivery may be required within minutes if CPR does not restore normal maternal cardiopulmonary function and recovery of FHR.

#### When is scalp stimulation helpful?

Stimulation of the fetal scalp is an effective technique for assessing fetal status during periods of nonreassuring FHR patterns.<sup>18</sup> However, the technique is intended to be performed during periods of FHR baseline and is sometimes misapplied during prolonged decelerations. Scalp stimulation during a prolonged deceleration would not likely provide valid information or change clinical management and could in theory exacerbate fetal compromise if additional parasympathetic tone were elicited.

#### Avoid fetal pulse oximetry

Although fetal pulse oximetry is FDA-approved and commercially available in the United States, and may be well suited for monitoring fetal arrhythmias,<sup>19,20</sup> a pro-

longed deceleration is an absolute contraindication to its use.<sup>21</sup>

#### Summary

Overall, in managing a delivery marked by prolonged decelerations, we should strive to minimize maternal–fetal complications by carefully assessing the clinical situation, correcting reversible problems, and preparing for expeditious delivery if the fetal condition is of sufficient concern that further expectant management is unlikely to allow for safe spontaneous delivery. Still, “...bedside judgment inevitably will sometimes be imperfect given the unpredictability of these decelerations.”<sup>2</sup> ■

#### REFERENCES

1. Cetrulo CL, Schifrin BS. Fetal heart rate patterns preceding death in utero. *Obstet Gynecol.* 1976;48:521–527.
2. Cunningham FG, Leveno KJ, Bloom SL, et al. *Williams Obstetrics.* 22nd ed. New York: McGraw-Hill; 2005.
3. Electronic fetal heart rate monitoring: research guidelines for interpretation. National Institute of Child Health and Human Development Research Planning Workshop. *Am J Obstet Gynecol.* 1997;177:1385–1390.
4. Intrapartum fetal heart rate monitoring. ACOG Practice Bulletin #70. American College of Obstetricians and Gynecologists. *Obstet Gynecol.* 2005;106:1453–1461.
5. Young BK, Weinstein HM. Moderate fetal bradycardia. *Am J Obstet Gynecol.* 1976;126:271–275.
6. Young BK, Katz M, et al. Fetal blood and tissue pH with moderate bradycardia. *Am J Obstet Gynecol.* 1979;135:45–47.
7. Reynolds SR. Bradycardia in the lamb fetus in response to circulatory distress. *Am J Physiol.* 1954;176:169–174.
8. Langer O, Sonnendecker EW. Characteristics and management of intrapartum prolonged fetal bradycardia. *Br J Obstet Gynaecol.* 1982;89:904–912.
9. Williams KP, Galemeau F. Fetal heart rate parameters predictive of neonatal outcome in the presence of a prolonged deceleration. *Obstet Gynecol.* 2002;100:951–954.
10. Ziliani M, Segura CL, et al. Studies on fetal bradycardia during birth process. II. *Obstet Gynecol.* 1973;42:840–843.

#### FAST TRACK

**Fetal scalp stimulation to assess fetal status should be done during periods of FHR baseline**

CONTINUED

**TABLE 4**

**Stepwise management of prolonged decelerations**

**Examine the cervix**

- Check for umbilical cord prolapse
- Check progress of dilation and descent
- Place internal monitors, if indicated

**Determine probable cause**

**Start therapies**

**Prepare for intervention by operative delivery**

- Intravenous access
- Blood type and screen
- Indwelling urinary catheter
- Obtain consents for operative vaginal delivery and cesarean delivery
- Notify appropriate personnel (eg, anesthesiology, pediatrics)

**Deliver**

- If fetal condition is nonreassuring despite therapies
- If prolonged decelerations recur and spontaneous delivery is remote (cases must be individualized)

11. Leung AS, Leung EK, Paul RH. Uterine rupture after previous cesarean delivery: maternal and fetal consequences. *Am J Obstet Gynecol.* 1993;169:945–950.

12. Freeman RK, Garite TG, Nageotte MP. *Fetal Heart Rate Monitoring.* Philadelphia: Lippincott Williams & Wilkins; 2003.

13. Miyazaki FS, Taylor NA. Saline amnioinfusion for relief of

variable or prolonged decelerations. A preliminary report. *Am J Obstet Gynecol.* 1983;146:670–678.

14. Hofmeyr GJ. Amnioinfusion for umbilical cord compression in labour. *Cochrane Database Syst Rev.* 2000:CD000013.

15. Gabbe SG, Nelson LM, Paul RH. Fetal heart rate response to acute hemorrhage. *Obstet Gynecol.* 1977;49:247–251.

16. Paul RH, Koh KS, Bernstein SG. Changes in fetal heart rate-uterine contraction patterns associated with eclampsia. *Am J Obstet Gynecol.* 1978;130:165–169.

17. Clark SL, Hankins GD, Dudley DA, Dildy GA, Porter TF. Amniotic fluid embolism: analysis of the national registry. *Am J Obstet Gynecol.* 1995;172:1158–1167; discussion 1167–1169.

18. Clark SL, Gimovsky ML, Miller FC. The scalp stimulation test: a clinical alternative to fetal scalp blood sampling. *Am J Obstet Gynecol.* 1984;148:274–277.

19. Dildy GA, Loucks CA, Clark SL. Intrapartum fetal pulse oximetry in the presence of fetal cardiac arrhythmia. *Am J Obstet Gynecol.* 1993;169:1609–1611.

20. van den Berg PP, Nijland R, van den Brand SF, Jongsma HW, Nijhuis JG. Intrapartum fetal surveillance of congenital heart block with pulse oximetry. *Obstet Gynecol.* 1994;84:683–686.

21. Garite TJ, Dildy GA, McNamara H, et al. A multicenter controlled trial of fetal pulse oximetry in the intrapartum management of nonreassuring fetal heart rate patterns. *Am J Obstet Gynecol.* 2000;183:1049–1058.

22. Gull I, Jaffa AJ, Oren M, Grisaru D, Peyser MR, Lessing JB. Acid accumulation during end-stage bradycardia in term fetuses: how long is too long? *Br J Obstet Gynaecol.* 1996;103:1096–1101.

The author reports no financial affiliations relevant to this article.

**The TRUSTED Choice  
for Adhesion Prevention**

**Gynecare**  
**Interceed**  
Absorbable Adhesion Barrier

**Helping Surgeons protect women for OVER 15 YEARS**

**INDICATIONS:** INTERCEED Barrier is indicated as an adjuvant in open (laparotomy) gynecologic pelvic surgery for reducing the incidence of postoperative pelvic adhesions after meticulous hemostasis is achieved consistent with microsurgical principles.

**CONTRAINDICATIONS:** The use of INTERCEED (TC7) Absorbable Adhesion Barrier is contraindicated in the presence of frank infection. INTERCEED Barrier is not indicated as a hemostatic agent. Appropriate means of achieving hemostasis must be employed.

**WARNINGS:** The safety and effectiveness of INTERCEED Barrier in laparoscopic surgery or any procedures other than open (laparotomy) gynecologic microsurgical procedures have not been established.

Postoperative adhesions may be induced by INTERCEED Barrier application if adjacent tissues (e.g., ovary and tube) and structures are coated or conjoined by the device, or if INTERCEED Barrier is folded, wadded or layered. Postoperative adhesions may occur in the presence of INTERCEED Barrier if meticulous hemostasis is not achieved prior to application. As with all foreign substances, INTERCEED Barrier should not be placed in a contaminated surgical site.

**PRECAUTIONS:** Use only a single layer of INTERCEED Barrier, since multiple layers of packing or folding will not enhance the adhesion barrier characteristics and may interfere with the absorption rate of INTERCEED Barrier. Care should be exercised in applying INTERCEED Barrier to a pelvic organ not to constrict or restrict it. If the product comes in contact with blood prior to completing the procedure, it should be discarded, as fibrin deposition cannot be removed by irrigation and may promote adhesions formation. Ectopic pregnancies have been associated with fertility surgery of the female reproductive tract. No data exist to establish the effect, if any, of INTERCEED Barrier on the occurrence of ectopic pregnancies. No adequate studies have been conducted in women who have become pregnant within the first month after exposure to INTERCEED Barrier. No teratogenic studies have been performed. Therefore, avoidance of conception should be considered during the first complete menstrual cycle after use of INTERCEED Barrier. The safety and effectiveness of using INTERCEED Barrier in combination with other adhesion prevention treatments have not been clinically established. INTERCEED Barrier is supplied sterile. As the material is not compatible with autoclaving or ethylene oxide sterilization, INTERCEED Barrier must not be resterilized. Foreign body reactions may occur in some patients. Interactions may occur between INTERCEED Barrier and some drugs used at the surgical site. Pathologists examining sites of INTERCEED Barrier placement should be made aware of its usage and of the normal cellular response to INTERCEED Barrier to facilitate proper evaluation of specimens.

**ADVERSE REACTIONS:** The type and frequency of adverse events reported are consistent with events typically seen following surgery. Postsurgical adhesions may occur in the presence of INTERCEED Barrier.

Refer to package insert for complete instructions for use, warnings and precautions.

ETHICON Women's Health & Urology  
A Division of ETHICON, Inc. a **Johnson & Johnson** company

[www.gynecare.com](http://www.gynecare.com) • 1-888-GYNECARE  
© 2006 ETHICON, INC. \*Trademark

**Circle #198 on Reader Response Card**